For years, drug development for Huntington’s disease has focused on reducing the toxic huntingtin protein produced by the mutant HTT gene. That strategy remains active, but a second therapeutic direction is gaining momentum: preventing the DNA mutation itself from becoming more dangerous over time.
Researchers now understand that the CAG repeat expansion that causes Huntington’s disease is not fixed at birth. In vulnerable neurons, the repeated DNA sequence can continue to lengthen throughout life. When those repeats reach a critical range, cellular function begins to deteriorate rapidly. This growing understanding of somatic expansion is reshaping how scientists think about when and where to intervene.
A Mutation That Keeps Changing
Huntington’s disease is caused by an expanded CAG sequence in the HTT gene. People who inherit more than 40 repeats are highly likely to develop the disease, but repeat length alone does not fully explain when symptoms begin.
Genetic studies have shown that variants in DNA-repair genes can shift disease onset earlier or later than expected. This led researchers to investigate whether the cell’s own repair machinery might contribute to further repeat expansion over time.
Work in postmortem human neurons provided important support for that idea. Researchers found that repeat growth accelerated if CAG tracts approached roughly 80 copies. Beyond about 150 repeats, gene regulation became increasingly abnormal and neuronal degeneration followed.
“It’s like going over a waterfall,” said Steve McCarroll, a neurogeneticist at Harvard Medical School, describing the long period of relative stability followed by rapid decline. The findings suggest that Huntington’s disease may unfold in stages, creating a potentially lengthy interval during which DNA expansion is occurring before substantial neuronal loss becomes irreversible.
DNA Repair Becomes a Therapeutic Target
A body of emerging drug discovery research has focused on MSH3, a gene involved in correcting DNA mismatches. In the context of Huntington’s disease, that repair process can inadvertently lengthen the CAG repeat.
Human genetic studies have linked natural variation in MSH3 to differences in repeat expansion and disease progression. Animal studies have strengthened the case by showing that reducing MSH3 activity can slow or nearly halt expansion in neurons.
That makes MSH3 an attractive target, though not a simple one. DNA repair is essential for maintaining genomic stability, so developers must determine how much activity can be reduced safely and where suppression should occur.
Several companies are now pursuing different approaches, including gene therapies delivered directly into the brain or cerebrospinal fluid and small molecules designed to cross the blood-brain barrier.
The broader implication is significant. Other disorders, including myotonic dystrophy and spinocerebellar ataxias, are also driven by unstable repeat expansions. A successful strategy in Huntington’s disease could therefore have relevance well beyond one rare disorder.
Huntingtin Lowering Still Has a Role
The upstream strategy does not replace efforts to reduce mutant huntingtin itself. For example, uniQure’s AMT-130 gene therapy provided important evidence that lowering huntingtin may alter the course of disease. The therapy uses an adeno-associated virus to deliver genetic instructions for a microRNA designed to reduce production of huntingtin.
In a Phase I/II study, high-dose AMT-130 slowed disease progression by 75% at 36 months on the composite Unified Huntington’s Disease Rating Scale compared with a propensity score-matched external control. Total functional capacity also declined more slowly and cerebrospinal fluid neurofilament light, a biomarker associated with neuronal injury, remained below baseline on average.
The study has limitations. It involved a relatively small number of treated patients and relied on external controls rather than a conventional placebo-controlled comparison for the primary analysis. The therapy also requires stereotactic neurosurgical delivery directly into the brain.
A New Development Strategy Takes Shape
Huntington’s disease research may ultimately need both approaches. Targeting somatic expansion could slow the genetic process that drives neurons toward dysfunction, while huntingtin-lowering therapies could reduce the toxic protein already produced in affected cells. Researchers are now considering whether those strategies could eventually be combined.
For drug developers, the shift raises important questions about treatment timing, target validation and clinical trial design. Intervening earlier may require identifying patients before substantial neuronal loss occurs, while biomarkers such as neurofilament light may help evaluate whether a therapy is affecting disease biology before clinical changes become obvious.
Huntington’s disease research has moved beyond a single therapeutic hypothesis. By targeting both the expanding mutation and its downstream consequences, researchers are developing a broader strategy to slow a disease once considered genetically inevitable.
Did you enjoy this blog post? Check out our other blog posts as well as related topics on our Webinar page.
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.